UK pharma major GlaxoSmithKline (LSE: GSK) has announced positive headline results in the innovative Salford Lung Study in chronic obstructive pulmonary disease (COPD).
The pioneering study is a Phase IIIb multi-center, open label randomized controlled trial (RCT) comparing the effectiveness and safety profile of Relvar Ellipta (Breo Ellipta in the US) (FF/VI) 100/25mcg with existing COPD usual care.
Initial results show that FF/VI achieved a superior reduction in exacerbations versus usual care, which included long-acting muscarinic antagonists (LAMA). Long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS), administered as a monotherapy, dual or triple combinations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze